VNS Therapy
Device
LivaNova USA, Inc.
Total Payments
$70.9M
Transactions
35,603
Doctors
6,128
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $6.4M | 2,618 | 354 |
| 2023 | $4.4M | 1,725 | 317 |
| 2022 | $2.4M | 1,485 | 308 |
| 2021 | $3,225 | 2 | 2 |
| 2020 | $14.9M | 4,355 | 1,611 |
| 2019 | $17.1M | 9,149 | 2,589 |
| 2018 | $15.1M | 8,146 | 2,618 |
| 2017 | $10.5M | 8,123 | 2,432 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $43.8M | 16 | 61.7% |
| Unspecified | $20.5M | 3,020 | 28.9% |
| Travel and Lodging | $2.0M | 5,827 | 2.8% |
| Food and Beverage | $1.3M | 24,958 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 586 | 1.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1.1M | 682 | 1.6% |
| Consulting Fee | $874,660 | 425 | 1.2% |
| Honoraria | $30,600 | 23 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $26,500 | 13 | 0.0% |
| Debt forgiveness | $23,481 | 10 | 0.0% |
| Grant | $19,750 | 10 | 0.0% |
| Gift | $15,686 | 8 | 0.0% |
| Education | $11,375 | 22 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,125 | 1 | 0.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $1,000 | 2 | 0.0% |
Payments by Type
General
$50.4M
32,583 transactions
Research
$20.5M
3,020 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| (OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation | LivaNova USA, Inc. | $7.7M | 0 |
| ANTHEM HFrEF | LivaNova USA, Inc. | $3.1M | 0 |
| RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression | LivaNova USA, Inc. | $2.6M | 0 |
| Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy | LivaNova USA, Inc. | $902,025 | 0 |
| ANTHEM-HFrEF | LivaNova USA, Inc. | $890,088 | 0 |
| Microburst Study | LivaNova USA, Inc. | $874,635 | 0 |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | LivaNova USA, Inc. | $819,255 | 2 |
| Microburst VNS Therapy Feasibility Study in Subjects with Refractory Epilepsy | LivaNova USA, Inc. | $653,052 | 2 |
| RECOVER: A Prospective, Multi-Center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No-Stimulation Control in Subjects with Treatment Resistant Depression | LivaNova USA, Inc. | $466,299 | 0 |
| (THN3)Targeted Hypoglossal Neurostimulation Study #3 | LivaNova USA, Inc. | $430,123 | 0 |
| Core-VNS LNN-801 | LivaNova USA, Inc. | $272,801 | 0 |
| E41 Microburst Study | LivaNova USA, Inc. | $239,839 | 2 |
| Identifying MEG-derived functional connectivity signatures as potential biomarkers for response to VNS therapy in children with refractory epilepsy | LivaNova USA, Inc. | $237,763 | 0 |
| The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) | LivaNova USA, Inc. | $218,956 | 0 |
| Patterns Of Care In Childhood Epilepsy: Use Of Vagus Nerve Stimulation in US Hospitals | LivaNova USA, Inc. | $170,737 | 0 |
| Mechanisms of Vagus Nerve Stimulation for the Control of Neurodegeneration in Parkinson's Disease | LivaNova USA, Inc. | $137,044 | 0 |
| RECOVER: A Prospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects with Treatment-Resistant Depression | LivaNova USA, Inc. | $124,000 | 0 |
| Functional Validation of the Imthera Lead to Limit Off-Target Effects of Cervical Vagus Stimulation | LivaNova USA, Inc. | $111,800 | 0 |
| VNS Effects on Rescue Medications Usage: Retrospective Study | LivaNova USA, Inc. | $84,848 | 0 |
| Treatment Predicting Seizure Outcome and Investigating Re-organization of Brain Network | LivaNova USA, Inc. | $71,669 | 0 |
Top Doctors Receiving Payments for VNS Therapy
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Neurology | Kansas City, KS | $43.8M | 16 |
| Unknown | — | Fargo, ND | $20.5M | 3,040 |
| Ahmed Abdelmoity | Neurology with Special Qualifications in Child Neurology | Overland Park, KS | $452,295 | 521 |
| , MD | Psychiatry | Dallas, TX | $258,236 | 75 |
| , M.D | Internal Medicine | Parker, CO | $242,321 | 392 |
| , MD | Neurology | Tampa, FL | $176,167 | 340 |
| , M.D | Surgery | Huntington, WV | $154,135 | 168 |
| , MD | Clinical Neurophysiology | Chicago, IL | $150,410 | 243 |
| , MD | Pediatrics | Phoenix, AZ | $149,582 | 167 |
| , M.D | Psychiatry | Baltimore, MD | $146,387 | 92 |
| , MD | Neurology | Cincinnati, OH | $115,825 | 222 |
| , MD | Neurodevelopmental Disabilities | N White Plains, NY | $103,939 | 146 |
| , MD PC | Vascular Surgery | Olean, NY | $87,386 | 38 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Los Angeles, CA | $86,373 | 132 |
| , MD | Neurology | Billings, MT | $85,895 | 125 |
| , MD | Neurology | Louisville, KY | $83,064 | 129 |
| , MD | Clinical Neurophysiology | Los Angeles, CA | $83,063 | 131 |
| , MD | Neurology | Albany, NY | $72,781 | 120 |
| , MD | Epilepsy | New York, NY | $69,274 | 62 |
| , MD | Psychiatry | Saint Louis, MO | $67,131 | 34 |
| Jerzy Szaflarski | Neurology | Cincinnati, OH | $56,613 | 21 |
| , MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $56,546 | 78 |
| , MD | Cardiovascular Disease | Boston, MA | $46,744 | 7 |
| , DO | Neurology with Special Qualifications in Child Neurology | Richmond, VA | $45,497 | 76 |
| , MD | Neurology | Pittsburgh, PA | $42,230 | 124 |
Ad
Manufacturing Companies
- LivaNova USA, Inc. $65.5M
- Cyberonics, Inc. $5.4M
Product Information
- Type Device
- Total Payments $70.9M
- Total Doctors 6,128
- Transactions 35,603
About VNS Therapy
VNS Therapy is a device associated with $70.9M in payments to 6,128 healthcare providers, recorded across 35,603 transactions in the CMS Open Payments database. The primary manufacturer is LivaNova USA, Inc..
Payment data is available from 2017 to 2024. In 2024, $6.4M was paid across 2,618 transactions to 354 doctors.
The most common payment nature for VNS Therapy is "Royalty or License" ($43.8M, 61.7% of total).
VNS Therapy is associated with 20 research studies, including "(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation" ($7.7M).